NCT00796510View on ClinicalTrials.gov

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Pulmonary Arterial HypertensionPulmonary Hypertension
Interventions
DRUG

Sitaxsentan

Sitaxsentan = 100 mg tablet administered orally, once daily

DRUG

Sitaxsentan and Sildenafil

Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day

Trial Locations (3)

92708

Pfizer Investigational Site, Fountain Valley

400 001

Pfizer Investigational Site, Cluj-Napoca

Unknown

Pfizer Investigational Site, Kyiv

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00796510 - Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety | Biotech Hunter | Biotech Hunter